Management and survival rates in patients with glioma in China (2004-2010): A retrospective study from a single-institution

Journal of Neuro-Oncology

Volumn 113, Issue 2, 2013, Pages 259-266

  Yang, Pei ^a,b   Wang, Yongzhi ^a,b   Peng, Xiaoxia ^b   You, Gan ^a,b   Zhang, Wei ^a,b   Yan, Wei ^a,b   Bao, Zhaoshi ^a,b   Wang, Yinyan ^a,b   Qiu, Xiaoguang ^a,b   Jiang, Tao ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Asians; Clinical features; Glioma; Prognosis; Survival

Indexed keywords

KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINA; CLINICAL FEATURE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT CARE; PREOPERATIVE EVALUATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SYMPTOM; ADOLESCENT; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAIN NEOPLASMS; CHINA; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879081190     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1103-9     Document Type: Article

References (45)

1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93-108. doi: 10.1007/s00401-005-0991-y
2. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde registry for the period 2000-2007. Neuro-Oncology 13(12):1370-1378. doi: 10.1093/neuonc/nor120
3. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F (2011) National comprehensive cancer network clinical practice guidelines in oncology: head and neck cancers. J Natl Compr Cancer Netw (JNCCN) 9(6):596-650
4. Stupp R, Pavlidis N, Jelic S (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16(Suppl 1):i64-i65. doi: 10.1093/annonc/mdi834
5. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER (2005) Patterns of care for adults with newly diagnosed malignant glioma. J Am Med Assoc (JAMA) 293(5):557-564. doi: 10.1001/jama.293.5.557
6. Thurnher MM (2009) 2007 World Health Organization classification of tumours of the central nervous system. Cancer imaging: the official publication of the International Cancer Imaging Society 9 Spec No. A:S1-3. doi: 10.1102/1470-7330.2009.9001
7. Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neuro-Oncol 58(3):217-236
8. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11(14):5167-5174. doi: 10.1158/1078-0432.CCR-05-0230
9. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broet P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58(2):322-326. doi: 10.1002/ana.20543
10. Stupp R, Roila F (2009) Malignant glioma: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):126-128. doi: 10.1093/annonc/mdp151
11. Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, Krengli M, Maluta S, Parisi S, Bertoni F, Mantovani C, Tombolini V, De Renzis C, Lioce M, Fatigante L, Fusco V, Muto P, Berti F, Rubino G, Cipressi S, Fariselli L, Lupattelli M, Santoni R, Pirtoli L, Biti G (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67(2):446-458. doi: 10.1227/01.NEU.0000371990.86656.E8
12. Kang SG, Kim JH, Nam DH, Park K (2005) Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol medico-chirurgica 45(5):232-238 discussion 238-239
13. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003) Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129(8):477-484. doi: 10.1007/s00432-003-0471-5
14. Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M (2008) Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme". La Clin terap 159(4):233-238
15. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Song YJ, Kang CS, Jiang T (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro-Oncology 14(2):230-241. doi: 10.1093/neuonc/nor205
16. Li S, Jiang T, Li G, Wang Z (2008) Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res 30(6):567-570. doi: 10.1179/174313208X297913
17. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9(1):29-38. doi: 10.1016/S1470-2045(07)70384-4
18. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T (2012) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. doi: 10.1002/cncr.27826
19. Zhang W, Yan W, You G, Bao Z, Wang Y, Liu Y, You Y, Jiang T (2013) Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. Cancer Lett 328(1):120-125. doi: 10.1016/j.canlet.2012.08.033
20. Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T (2012) Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology 14(12):1432-1440. doi: 10.1093/neuonc/nos263
21. Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-Oncology 14(4):518-525. doi: 10.1093/neuonc/nor232
22. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-Oncology 14(1):109-116. doi: 10.1093/neuonc/nor185
23. Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, Wang Y, Song Y, Li Y, Jiang T, Pu P, Jiang C, Kang C (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-Oncology 14(8):1026-1036. doi: 10.1093/neuonc/nos122
24. Zhang J, Huang K, Shi Z, Zou J, Wang Y, Jia Z, Zhang A, Han L, Yue X, Liu N, Jiang T, You Y, Pu P, Kang C (2011) High beta-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro-Oncology 13(6):600-609. doi: 10.1093/neuonc/nor034
25. Burton EC, Prados MD (2000) Malignant gliomas. Curr Treat Options Oncol 1(5):459-468
26. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190-198. doi: 10.3171/jns.2001.95.2.0190
27. Sawaya R (1999) Extent of resection in malignant gliomas: a critical summary. J Neuro-Oncol 42(3):303-305
28. Li S, Zhang W, Chen B, Jiang T, Wang Z (2010) Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. Neurol Res 32(7):690-694. doi: 10.1179/016164109X12478302362536
29. Westermark B (2012) Glioblastoma-a moving target. Upsala J Med Sci 117(2):251-256. doi: 10.3109/03009734.2012.676574
30. Fedrigo CA, Grivicich I, Schunemann DP, Chemale IM, dos Santos D, Jacovas T, Boschetti PS, Jotz GP, Braga AF, da Rocha AB (2011) Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol 6:156. doi: 10.1186/1748-717X-6-156
31. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology 14(6):712-719. doi: 10.1093/neuonc/nos089
32. Hagerstrand D, Lindh MB, Pena C, Garcia-Echeverria C, Nister M, Hofmann F, Ostman A (2010) PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology 12(9):967-975. doi: 10.1093/neuonc/noq029
33. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129-1133. doi: 10.1038/nature07443
34. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67(17):7960-7965. doi: 10.1158/0008-5472.CAN-07-2154
35. Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A (2006) High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66(15):7429-7437. doi: 10.1158/0008-5472.CAN-06-0712
36. Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG, Merlo A (1999) The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59(21):5479-5482
37. Paulus W (2009) GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol 118(5):603-604. doi: 10.1007/s00401-009- 0600-6
38. Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259-273
39. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916-926. doi: 10.1016/S1470- 2045(12)70265-6
40. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J obstet Gynecol 206(2):e119-e121. doi: 10.1016/j.ajog.2011.12.003
41. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21(8):1485-1491. doi: 10.1200/JCO.2003.10.035
42. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
43. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88(12):2887
44. Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC (2012) Relative survival of patients with supratentorial low-grade gliomas. Neuro-Oncology 14(8):1062-1069. doi: 10.1093/neuonc/nos144
45. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479-489